Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
ASL pushes for board shakeup at Avadel over handling of sleep drug rollout
09:41am, Monday, 30'th Jun 2025
ASL Strategic Value Fund on Monday urged shareholders of Avadel Pharmaceuticals to replace its board, citing mismanagement in the rollout of the drugmaker's flagship sleep disorder drug Lumryz since i
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders
07:00am, Monday, 30'th Jun 2025
GREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Phar
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 2
ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reports
10:30pm, Sunday, 29'th Jun 2025
ASL Strategic Value Fund plans to push shareholders of drugmaker Avadel Pharmaceuticals to vote to remove the company's board, citing mismanagement in the launch of its flagship sleep disorder drug, t
ASL Strategic Value Fund wants the narcolepsy drugmaker to retain investment bankers and consider a sale.
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 16'th Jun 2025
DUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?
10:56am, Monday, 16'th Jun 2025
The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock
01:20pm, Friday, 13'th Jun 2025
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM ha
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
04:05pm, Thursday, 29'th May 2025
– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who s
Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet
11:00am, Thursday, 29'th May 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positiv
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that memb
All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy
01:00pm, Thursday, 15'th May 2025
Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'
11:43am, Thursday, 15'th May 2025
Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
04:15pm, Tuesday, 13'th May 2025
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today
